125 related articles for article (PubMed ID: 9815278)
21. Nuclear immunolocalization of P-glycoprotein in multidrug-resistant cell lines showing similar mechanisms of doxorubicin distribution.
Baldini N; Scotlandi K; Serra M; Shikita T; Zini N; Ognibene A; Santi S; Ferracini R; Maraldi NM
Eur J Cell Biol; 1995 Nov; 68(3):226-39. PubMed ID: 8603675
[TBL] [Abstract][Full Text] [Related]
22. Effect of MDR modulators verapamil and promethazine on gene expression levels of MDR1 and MRP1 in doxorubicin-resistant MCF-7 cells.
Dönmez Y; Akhmetova L; İşeri ÖD; Kars MD; Gündüz U
Cancer Chemother Pharmacol; 2011 Apr; 67(4):823-8. PubMed ID: 20563580
[TBL] [Abstract][Full Text] [Related]
23. Effect of duration of exposure to S9788, cyclosporin A or verapamil on sensitivity of multidrug resistant cells to vincristine or doxorubicin.
Pérez V; Pierré A; Léonce S; Anstett M; Atassi G
Anticancer Res; 1993; 13(4):985-90. PubMed ID: 8352569
[TBL] [Abstract][Full Text] [Related]
24. Multidrug resistance circumvention by a new triazinoaminopiperidine derivative S9788 in vitro: definition of the optimal schedule and comparison with verapamil.
Julia AM; Roché H; Berlion M; Lucas C; Milano G; Robert J; Bizzari JP; Canal P
Br J Cancer; 1994 May; 69(5):868-74. PubMed ID: 8180016
[TBL] [Abstract][Full Text] [Related]
25. S9788 modulation of P-glycoprotein- and Multidrug-related protein-mediated multidrug resistance by Servier 9788 in doxorubicin-resistant MCF7 cells.
Bichat F; Solis-Recendez G; Poullain MG; Poupon MF; Khayat D; Bastian G
Biochem Pharmacol; 1998 Aug; 56(4):497-502. PubMed ID: 9763226
[TBL] [Abstract][Full Text] [Related]
26. Cellular pharmacology of lipophilic anthracyclines in human tumor cells in culture selected for resistance to doxorubicin.
Bennis S; Faure P; Chapey C; Hu YP; Fourche J; El Yamani J; Robert J
Anticancer Drugs; 1997 Jul; 8(6):610-7. PubMed ID: 9300576
[TBL] [Abstract][Full Text] [Related]
27. [In vitro characterization of S9788, a new modulator of multidrug resistance].
Pérez V; Pierré A; Léonce S; Anstett M; Prost JF; Atassi G
Bull Cancer; 1993 Apr; 80(4):310-25. PubMed ID: 8173185
[TBL] [Abstract][Full Text] [Related]
28. Reversal of multidrug resistance by transferrin-conjugated liposomes co-encapsulating doxorubicin and verapamil.
Wu J; Lu Y; Lee A; Pan X; Yang X; Zhao X; Lee RJ
J Pharm Pharm Sci; 2007; 10(3):350-7. PubMed ID: 17727798
[TBL] [Abstract][Full Text] [Related]
29. Evidence for cytoplasmic P-glycoprotein location associated with increased multidrug resistance and resistance to chemosensitizers.
Abbaszadegan MR; Cress AE; Futscher BW; Bellamy WT; Dalton WS
Cancer Res; 1996 Dec; 56(23):5435-42. PubMed ID: 8968098
[TBL] [Abstract][Full Text] [Related]
30. [Pharmacological properties of S9788, a new modulator of multidrug resistance].
Bull Cancer; 1994 Feb; 81(2):93-103. PubMed ID: 7894124
[TBL] [Abstract][Full Text] [Related]
31. Influence of S9788, a new modulator of multidrug resistance, on the cellular accumulation and subcellular distribution of daunorubicin in P-glycoprotein-expressing MCF7 human breast adenocarcinoma cells.
Merlin JL; Marchal S; Ramacci C; Dieterlen A; Schultz G; Lucas C; Poullain MG; Berlion M
Cytometry; 1995 Aug; 20(4):315-23. PubMed ID: 7587719
[TBL] [Abstract][Full Text] [Related]
32. 2-Pyrrolinodoxorubicin and its peptide-vectorized form bypass multidrug resistance.
Castex C; Merida P; Blanc E; Clair P; Rees AR; Temsamani J
Anticancer Drugs; 2004 Jul; 15(6):609-17. PubMed ID: 15205606
[TBL] [Abstract][Full Text] [Related]
33. Elevation of glucosylceramide in multidrug-resistant cancer cells and accumulation in cytoplasmic droplets.
Morjani H; Aouali N; Belhoussine R; Veldman RJ; Levade T; Manfait M
Int J Cancer; 2001 Oct; 94(2):157-65. PubMed ID: 11668492
[TBL] [Abstract][Full Text] [Related]
34. Time-lapse live cell imaging and flow analysis of multidrug resistance reversal by verapamil in bladder cancer cell lines.
Featherstone JM; Lwaleed BA; Speers AG; Hayes MC; Birch BR; Cooper AJ
Urology; 2009 Aug; 74(2):378-84. PubMed ID: 19501884
[TBL] [Abstract][Full Text] [Related]
35. Reversal of multidrug resistance by a new lipophilic cationic molecule, S9788. Comparison with 11 other MDR-modulating agents in a model of doxorubicin-resistant rat glioblastoma cells.
Huet S; Chapey C; Robert J
Eur J Cancer; 1993; 29A(10):1377-83. PubMed ID: 8398262
[TBL] [Abstract][Full Text] [Related]
36. Mitochondrial localization and activity of P-glycoprotein in doxorubicin-resistant K562 cells.
Munteanu E; Verdier M; Grandjean-Forestier F; Stenger C; Jayat-Vignoles C; Huet S; Robert J; Ratinaud MH
Biochem Pharmacol; 2006 Apr; 71(8):1162-74. PubMed ID: 16499877
[TBL] [Abstract][Full Text] [Related]
37. Modulation of adriamycin cytotoxicity and transport in drug-sensitive and multidrug-resistant Chinese hamster ovary cells by hyperthermia and cyclosporin A.
Larrivée B; Averill DA
Cancer Chemother Pharmacol; 2000; 45(3):219-30. PubMed ID: 10663640
[TBL] [Abstract][Full Text] [Related]
38. Coformulation of doxorubicin and curcumin in poly(D,L-lactide-co-glycolide) nanoparticles suppresses the development of multidrug resistance in K562 cells.
Misra R; Sahoo SK
Mol Pharm; 2011 Jun; 8(3):852-66. PubMed ID: 21480667
[TBL] [Abstract][Full Text] [Related]
39. Modulation of anthracycline accumulation and metabolism in rat hepatocytes in culture by three revertants of multidrug resistance.
Le Bot MA; Kernaleguen D; Robert J; Berlion M; Riché C
Cancer Chemother Pharmacol; 1994; 35(1):53-8. PubMed ID: 7987977
[TBL] [Abstract][Full Text] [Related]
40. Doxorubicin-loaded nanospheres bypass tumor cell multidrug resistance.
Cuvier C; Roblot-Treupel L; Millot JM; Lizard G; Chevillard S; Manfait M; Couvreur P; Poupon MF
Biochem Pharmacol; 1992 Aug; 44(3):509-17. PubMed ID: 1354963
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
